Physician profile
Sol Velezcortes
NPI 1760469332
$7,888.13
in general payments reported to CMS, 2019-2025
51 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $772 · 2021: $1,634 · 2022: $1,294 · 2023: $1,457 · 2024: $1,910 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.00 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $492.56 | 2022-2025 | Kisunla, Amyvid, Jardiance |
| Tanabe Pharma America, INC. | $451.25 | 2020-2024 | |
| Avanir Pharmaceuticals, INC. | $450.67 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $405.99 | 2021-2024 | Ultomiris |
| Eisai INC. | $389.55 | 2021-2024 | |
| Argenx US, INC. | $388.17 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Abbott Laboratories | $368.32 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $330.78 | 2020-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $321.64 | 2019-2024 | |
| Ucb, INC. | $300.64 | 2022-2024 | Zilbrysq, Rystiggo |
| Abbvie INC. | $286.61 | 2021-2024 | Duopa |
| Bayer Healthcare Pharmaceuticals INC. | $279.08 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $275.05 | 2023-2025 | Nuedexta, Rexulti |
| Janssen Pharmaceuticals, INC | $264.93 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $263.21 | 2023-2025 | Farxiga, Airsupra |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $233.30 | 2021-2024 | Inbrija, Ampyra |
| Biogen, INC. | $210.56 | 2020-2024 | Vumerity, Aduhelm |
| Neurelis, INC. | $203.97 | 2021-2024 | Valtoco |
| Adamas Pharmaceuticals, INC. | $176.03 | 2019-2021 | |
| Csl Behring | $167.58 | 2019-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $166.12 | 2023-2024 | Austedo Xr |
| Mdd US Operations, LLC | $115.09 | 2020-2023 | Apokyn |
| Amgen INC. | $103.61 | 2022-2023 | Aimovig |
| Glaxosmithkline, LLC. | $102.09 | 2021 | |
| Lundbeck LLC | $96.91 | 2019-2024 | Vyepti, Rexulti |
| Boston Scientific Corporation | $85.08 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $79.86 | 2022-2024 | Ongentys, Ongentys 50mg Capsules 30, Crexont |
| Celgene Corporation | $77.72 | 2021-2022 | |
| Harmony Biosciences LLC | $74.62 | 2021 | |
| Philips North America LLC | $64.70 | 2021 | |
| Pfizer INC. | $64.53 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.93 | 2022 | |
| Akcea Therapeutics, INC. | $48.68 | 2020-2021 | |
| Chiesi USA, INC. | $42.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.73 | 2020 | |
| Livanova USA, INC. | $42.50 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $41.15 | 2019 | |
| Grifols USA, LLC | $34.88 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $34.11 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $29.96 | 2021 | |
| Novo Nordisk INC | $24.97 | 2020 | |
| Jazz Pharmaceuticals INC. | $22.61 | 2021 | |
| Genzyme Corporation | $22.40 | 2022 | |
| Stryker Corporation | $20.84 | 2023 | Ozark Cervical Plate System |
| Esperion Therapeutics, INC. | $20.72 | 2021 | |
| Silk Road Medical, INC. | $20.56 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.33 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.67 | 2019 | |
| Sobi, INC | $15.34 | 2021 | |
| Linus Health, INC. | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sol Velezcortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.